Clinical Trial Update: A Study Evaluating Daily Oral Doses of TLC-3595 in Participants With Insulin Resistance [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating daily oral TLC-3595 in insulin resistance is active but not recruiting. Sponsored by OrsoBio, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insulin Resistance

Drugs mentioned

• TLC-3595

Snippet

Sponsor: OrsoBio, Inc | Conditions: Insulin Resistance | Phase 2 | Status: ACTIVE_NOT_RECRUITING